Servier shared a post on LinkedIn:
“As part of our Servier 2030 ambition, we are focusing our RandD efforts on neurology in addition to oncology. To that end, we are targeting three families of neurological disease: refractory epilepsy, rare movement disorders, and neuromuscular diseases.
In order to build a robust and promising RandD pipeline in neurology, we are dedicating significant resources and investments, particularly for the development of new drugs that slow the progression of neurological disorders or significantly alleviate their symptoms. To date, this pipeline comprises 9 research projects and 3 development projects.
This year, we have expanded our pipeline with a first asset in autism spectrum disorder through the acquisition of a potential treatment for Fragile X syndrome.”
Proceed to the video attached to the post.
More posts featuring Servier.